V-Card | Print | PDF | Email Page

Renaud Bonnet

Practice Leader Private Equity


(T) +
(F) +


  • Columbia University (LL.M. 1997; Harlan Fiske Stone Scholar); Université de Paris II-Panthéon Assas (DESS/DJCE in Business Law and Taxation 1994; Double Maîtrise with honors and high honors 1993); ESSEC Graduate School of Management (MBA 1993); Institut d'Etudes Politiques de Paris (Sciences Po) (Diplôme — section Service Public 1991)

Bar Admissions

  • Paris and New York Bars

Renaud Bonnet co-chairs Jones Day's global Private Equity Practice and his areas of practice include venture capital, private equity, M&A, and capital markets.

Renaud primarily represents technology and life sciences companies, as well as the private equity and industrial investors that finance them, at every stage of development from entrepreneurial start-ups to multibillion dollar global corporations. He has acted as principal lawyer in a significant number of early to late stage financing rounds, LBO and other M&A transactions, joint ventures, initial public offerings, rights issues, private placements, and tender offers.

Renaud's recent experience includes representations of technology and life sciences companies Adocia, Assystem, Cellectis, Criteo, Devialet, Diaxonhit, EcoVadis, HRA Pharma, Ivalua, Mauna Kea Technologies, Microwave Vision, Mirakl, Nanobiotix, Onxeo, Orolia, Prodways, Stentys, Talend, Trace One, TxCell, Voltalia, and Voluntis. His recent investor-side representations include: Abingworth, Alven, Balderton, Bpifrance, Elaia, Felix Capital, Goldman Sachs, Orange, Hi Inov, Idinvest, Omnes, Seventure Partners, and Sofinnova.

Illustrative transactions in which Renaud acted as lead lawyer include: representing the issuer and/or underwriters in more than 40 IPOs on Alternext or the main French market; the IPOs of Criteo, Cellectis, and Talend on NASDAQ; the tender offers on Completel, Wavecom, and Assystem; the LBOs of HRA Pharma by Astorg and Goldman Sachs and of Orolia by Eurazeo; the sale of Novexel to AstraZeneca and of Trace One to Hgcapital; and the latest financing rounds of Devialet, Actility, and Ivalua.

Renaud is a member of the Consultative Commission on Issuers' Transactions and Financial Information of the French Financial Markets Authority (AMF).

Honors & Distinctions

  • Leading lawyer in France (annually) for private equity/venture capital, equity capital markets, M&A, and life sciences (Chambers, The Legal 500, Private Equity Magazine)

    Acknowledged as the #1 venture capital team in France since 2000 in top legal rankings

    1st prize for IPOs and capital markets, Le Magazine des Affaires (2016, 2015)


English, French
Renaud Bonnet